WILEX AG (WLXMF.PK) reported net loss of 2.6 million euros or 0.11 euros per share for the first quarter compared to the loss of 6 million euros or 0.32 euros per share a year ago.
Sales revenue for the three-month period surged to 3.7 million euros from 71 thousand euros in the prior year, mainly benefiting from sales revenue of 2.9 million euros in the Rx segment from the ongoing pro rata accrual of payments for RENCAREX.
Peter Llewellyn-Davies, chief financial officer of WILEX, stated, "We are pleased with our performance in the first quarter of 2012. The successful rights issue generated gross proceeds of EUR 9.9 million for the further funding of our studies, and we reported on several milestones and activities. Our earnings improved significantly year on year."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.